To include your compound in the COVID-19 Resource Center, submit it here.

DSC127: Additional Phase II data

Additional data from a double-blind, U.S. Phase II trial in patients with diabetic foot ulcers showed that 0.03% topical DSC127 led to a greater proportion of patients with complete healing of

Read the full 313 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE